Aegros: A Good Time to Invest
The Australian Financial Review (AFR) today featured a write-up on everyone’s favourite new fractionator: Aegros. Image: Founders Professor Hari Nair and Mr John Manusu proudly display the Aegros HaemaFrac®, which is set to revolutionise plasma fractionation in Australia and around the world. The AFR article covers: The 30-year maturity of the company’s HaemaFrac® technology, The […]
The Prime Minister and Aegros
Co-Founder and Executive Chair of Aegros, Professor Hari Nair, was pleased to attend a private evening function at Kirribilli House on Friday 30 September, where he met with Prime Minister the Hon Anthony Albanese, for a social evening and to discuss with him the essential role Aegros can play in Australia’s health infrastructure. The exclusive […]
Aegros in the Spotlight
More vision has appeared of Aegros Founder and Managing Director, John Manusu, at the Venture & Capital Conference, held at the University of Technology Sydney in July. After John addressed the gathering of investors in emerging health and technology investment opportunities, John paused to be interviewed by the Wholesale Investor media team. You can watch […]
HaemaFrac® TV at ASCIA 2022
As part of Aegros’ physical and virtual booths at the ASCIA 2022 conference, we presented a short video by Prof Hari Nair on the technology that powers the HaemaFrac® and on the results of the research we have undertaken in conjunction with the Kirby Institute.
Aegros Conference Poster ASCIA 2022
Aegros was proud to attend and sponsor the 32nd Annual Conference of the Australasian Society of Clinical Immunology and Allergy, held Aug 30 – 2 September in Melbourne. An Aegros and Kirby Institute research paper was featured at the conference, and the poster and abstract for this paper are available below. ABSTACT: ANTI-SARS-COV-2 HYPERIMMUNE GLOBULIN […]
The University of Queensland and Aegros Celebrates Co-founder’s Professorship
Professor Hari Nair, Aegros Co-founder and Executive Chair has been acknowledged by UQ with the conferral of an Adjunct Professorship.
Aegros on Proactive – It’s Time To Invest
Co-founder and Managing Director of Aegros, John Manusu, was interviewed recently by Proactive, a UK-based market report media outlet that covers the world’s major stock markets, to deliver the latest information regarding Aegros’ operations. There is currently a lot happening at Aegros. The world is still adjusting to the reality that global blood plasma supply […]
Aegros and UTS Prepare For Next Generation Science
Pioneering academic scientist Dr Majid E Warkiani of the University of Technology Sydney’s (UTS) School of Biomedical Engineering and Aegros’ science teams, are offering internships from all academic stages, to enhance students’ commercialisation, know-how, and to provide them with practical experience in the kinds of leading edge science needed to meet the challenges of the […]
Meta-analysis of Clinical Trial Studies Shows the Promise of Covimmune™
A recently released academic review of 37 randomised trials examines the effectiveness of neutralising antibodies for Covid-19, and reports good news for the effectiveness of Covimmune™, Aegros’ first hyperimmune product. Reviewed by Aegros’ Medical team, an outline of this important paper is below. Source: Determinants of passive antibody effectiveness in SARS-CoV-2 infection | medRxiv Review: […]
The Global Blood Plasma Supply Pinch Point
Business Insider investigates why two-thirds of the worlds blood plasma for fractionation comes from the USA.
